At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 448 enrolled
Drug / intervention
LY2439821 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy
In Brief
A Phase 2 clinical trial evaluating LY2439821 and Placebo for Rheumatoid Arthritis. Completed, enrolled 448 participants across 75 sites in 11 countries.
Detailed Summary
The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA): * The safety of LY2439821 and any side effects that might be associated with it. * Whether LY2439821 can help participants with active RA. * How much LY2439821 should be given to participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Chile, Germany, India, Peru, Poland, Romania, Russia, South Korea, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedAug 2009
Primary CompletionMar 2011
Study CompletionJun 2012
TodayJul 2026
First PostedAug 27, 2009
Enrollment StartAug 1, 2009
Primary CompletionMar 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 16.8 years ago
Interventions
LY2439821biological
Subcutaneous
Placebodrug
Subcutaneous